Zentalis Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2019 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Zentalis Pharmaceuticals, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2019 to Q2 2024.
  • Zentalis Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $12.7M, a 4.73% decline year-over-year.
  • Zentalis Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $53.3M, a 13.4% increase year-over-year.
  • Zentalis Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $54.8M, a 17% increase from 2022.
  • Zentalis Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $46.8M, a 31.1% increase from 2021.
  • Zentalis Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $35.7M, a 54.4% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $53.3M $12.7M -$631K -4.73% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-09
Q1 2024 $53.9M $12.8M -$900K -6.55% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $54.8M $13.9M +$4.27M +44.4% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-27
Q3 2023 $50.6M $13.9M +$3.55M +34.4% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-06
Q2 2023 $47M $13.3M -$3.42M -20.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 $50.4M $13.7M +$3.59M +35.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $46.8M $9.61M +$1.14M +13.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-27
Q3 2022 $45.7M $10.3M +$2.66M +34.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 $43M $16.8M +$6.85M +69% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-09
Q1 2022 $36.2M $10.1M +$456K +4.71% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $35.7M $8.47M +$584K +7.41% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-27
Q3 2021 $35.2M $7.66M +$407K +5.62% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $34.7M $9.92M +$2.24M +29.1% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $32.5M $9.69M +$9.36M +2846% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $23.1M $7.89M +$7.68M +3620% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-01
Q3 2020 $15.5M $7.25M +$7.09M +4577% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $8.38M $7.68M +$7.56M +6248% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-12
Q1 2020 $817K $329K +$200K +155% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 $617K $212K Oct 1, 2019 Dec 31, 2019 10-K 2022-02-24
Q3 2019 $155K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $121K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 $129K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.